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Graphical abstract 
 
 
Abstract 
Italy was the first European country hit by the COVID-19 pandemic and has the highest number 
of recorded COVID-19 deaths in Europe.  
This prospective cohort study of the correlates of the risk of death in COVID-19 patients was 
conducted at the Infectious Diseases and Intensive Care units of Luigi Sacco Hospital, Milan, 
Italy. The clinical characteristics of all the COVID-19 patients hospitalised in the early days of 
the epidemic (21 February -19 March 2020) were recorded upon admission, and the time-
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dependent probability of death was evaluated using the Kaplan-Meier method (censored as of 
20 April 2020). Cox proportional hazard models were used to assess the factors independently 
associated with the risk of death. 
Forty-eight (20.6%) of the 233 patients followed up for a median of 40 days (interquartile range 
33-47) died during the follow-up. Most were males (69.1%) and their median age was 61 years 
(IQR 50-72). The time-dependent probability of death was 19.7% (95% CI 14.6-24.9%) 30 
days after hospital admission. Age (adjusted hazard ratio [aHR] 2.08, 95% CI 1.48-2.92 per 
ten years more) and obesity (aHR 3.04, 95% CI 1.42-6.49) were independently associated with 
an increased risk of death, which was also associated with critical disease (aHR 8.26, 95% CI 
1.41-48.29), C-reactive protein levels (aHR 1.17, 95% CI 1.02-1.35 per 50 mg/L more) and 
creatinine kinase levels above 185 U/L (aHR 2.58, 95% CI 1.37-4.87) upon admission. 
Case-fatality rate of patients hospitalized with COVID-19 in the early days of the Italian 
epidemic was about 20%. Our study adds evidence to the notion that older age, obesity and 
more advanced illness are factors associated to an increased risk of death among patients 
hospitalized with COVID-19. 
 
Keywords: SARS-CoV-2; Italy; 30-day mortality; obesity; advanced age. 
 
1. INTRODUCTION 
In late December 2019, an outbreak of an emerging disease (COVID-19) caused by a novel 
coronavirus that was later named severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) was recorded in Wuhan, China [1], and subsequently rapidly spread to a substantial 
number of Asian and non-Asian countries. It was declared a pandemic by the World Health 
Organisation on 12 March 2020 [2].  
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The increasing number of studies conducted in Chinese hospitals over the last few months have 
contributed to delineating the characteristics of the disease and its lethality [3-6]. They describe 
COVID-19 as an atypical SARS-like pneumonia that requires intensive care in 26-33% of 
patients, 4-15% of whom eventually die [4, 5]. However, as the epidemic moves outside China, 
there is a need to verify the clinical features and lethality of COVID-19 in countries with 
different demographic characteristics.  
Italy was the first European country to be hit hard by the COVID-19 epidemic, with Lombardy 
in northern Italy being the region in which the first autochthonous cases were identified and 
the largest epidemic foci developed [7]. Italy is also the European country in which the highest 
number of COVID-19 deaths have so far been recorded (24,780 as of 27 April 2020) [8]. 
The Department of Infectious Diseases of Luigi Sacco Hospital (the national reference 
centre for epidemiological emergencies and bioterrorism in northern Italy) has been admitting 
SARS-CoV-2 patients (particularly those coming from the “red zone” municipalities first 
involved in the epidemic) since the night of 20 February 2020, when the first COVID-19 case 
was identified in a town about 50 km from Milan [9].  
This paper describes the demographic and clinical characteristics of the COVID-19 patients 
admitted to our hospital between 21 February and 19 March 2020 in the early stage of the 
Italian epidemic, and the factors associated with the risk of COVID-19-related death. 
2. MATERIALS AND METHODS  
2.1 Setting 
The study was conducted in the continuously evolving scenario created by the dramatic 
escalation of the COVID-19 epidemic in Lombardy. The large structural changes that had to 
be made in the organisation of our hospital over a 2-week period transformed our 68-bed 
Department of Infectious Diseases and 8-bed general intensive care unit (ICU) into a single-
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building isolation area with 93 non-intensive and 30 intensive care beds entirely dedicated to 
COVID-19 patients. 
2.2 Study design and participants 
This was a single-centre, prospective cohort study of all of the adult COVID-19 patients 
admitted to Luigi Sacco Hospital in Milan, Italy, between 21 February (the day the first patients 
were hospitalised) to 19 March 2020; the observation of the cohort was censored on 20 April 
2020. All of the study patients had COVID-19 confirmed by a positive real-time reverse-
transcription polymerase chain reaction on a nasopharyngeal swab.  
2.3 Data collection 
The data extracted from the patients' clinical charts on a daily basis and stored in an ad hoc 
database included age and gender; the reported date of symptom onset; body weight and height, 
the presence of  obesity defined as a body mass index ≥ 30 points [10], and history of smoking; 
comorbidity burden defined assessed by age unadjusted Charlson comorbidity index [11] and 
concomitant treatments for chronic medical conditions; symptoms; vital signs (heart rate, 
respiratory rate, blood pressure, pulse oximetry), laboratory values (white blood cell, 
neutrophil, lymphocyte, and platelet counts; hemoglobin, albumin, lactate dehydrogenase, C-
reactive protein (CRP), creatine kinase (CK), alanine aminotransferase, bilirubin, prothrombin, 
D-dimer, and creatinine levels; and arterial oxygen partial pressure); radiography findings upon 
admission. The chest X-ray images were reviewed and categorised as follows: no pathological 
findings; interstitial changes; monolateral lung consolidation(s); bilateral lung 
consolidation(s); and pleural effusion (yes/no). Oxygen therapy support started upon hospital 
admission, and its type (simple face mask, face mask with oxygen reservoir bag, Venturi-
type oxygen mask, continuous positive airway pressure device (cPAP), and mechanical 
ventilation) were collected. 
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Using the criteria proposed by Wu et al. [12], disease severity upon admission was classified 
as mild (mild clinical symptoms, no imaging signs of pneumonia); moderate (fever, cough, 
dyspnoea or other symptoms, imaging signs of pneumonia); severe (any of: respiratory distress 
with a respiratory rate (RR) of ≥30 breaths per minute; resting oxygen saturation in air ≤93%; 
or PaO2 / FiO2 ≤ 300 mmHg); and critical (any of respiratory failure requiring mechanical 
ventilation; shock; or any other organ failure needing intensive care).  
Data on the use of antivirals [lopinavir/ritonavir (LPV/r) and remdesivir], and/or antibiotic 
and/or immunomodulatory agents [hydroxychloroquine (HCQ), tocilizumab] during 
hospitalization were also collected. 
The primary outcome of interest was death; the life status of the patients discharged before the 
censoring date was ascertained by means of telephone calls made by two physicians on 20 
April, 2020. 
2.4 Data analysis 
The descriptive statistics include proportions for categorical variable, and median values and 
interquartile range (IQR) for continuous variables. The baseline demographic and clinico-
epidemiological characteristics of the survivors and non-survivors were compared using χ2 or 
Fisher's exact test where necessary for categorical variables and Wilcoxon’s rank-sum test for 
continuous variables. 
The time-dependent probability of death during the study period was assessed using the 
Kaplan-Meir method. 
The association(s) between clinically relevant, non-collinear and complete variables (without 
any missing data upon hospital admission) and the primary outcome was assessed by means of 
uni- and multivariable Cox proportional hazard models. The multivariable analysis was made 
by introducing into the model the variables that found to be significantly associated with 
outcome in the univariate analysis, as well as potential confounders. 
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All of the statistical analyses were made using SAS software, version 9.4, and differences 
with P values of <0.05 were considered statistically significant. 
The study was approved by our Comitato Etico Interaziendale Area 1. Informed consent was 
waived in the case of patients undergoing mechanical ventilation upon admission. 
 
3.0 RESULTS 
Between 21 February and 19 March 2020, a total of 233 COVID-19 patients were admitted to 
L. Sacco Hospital, Milan, Italy. Most were males (69.1%) of Italian nationality (92.8%), and 
their median age was 61 years (IQR 50-72). Twenty-six (11.2%) were healthcare workers. A 
total of 133 (57.1%) were resident in the city or metropolitan area of Milan (the first case in 
Milan was recorded on 23 February 2020). Twenty-seven (11.6%) came from the “red zones” 
and 71 were transferred from other provinces in Lombardy (Lodi, Cremona, and Bergamo) 
whose hospitals were overwhelmed by the sudden explosion of the epidemic.  
Forty-eight patients (20.6%) died during the study period, and 185 survived, including 162 
(69.5%) patients who were discharged, and 23 (9.9%) who were still hospitalised on the 
censoring date.  
Table 1 shows the differences in the baseline demographic and clinical characteristics of the 
survivors and non-survivors. The non-survivors included a higher proportion of subjects aged 
66-75 (39.6% vs 19.5%), 76-85 (20.8% vs 13.0%), and 86-95 years (10.4% vs 2.7%) (p<0.001); 
a higher proportion of patients transferred from other hospitals (62.5% vs 36.8%, p<0.002). 
The non-survivors were more frequently being treated with anti-platelet agents (p=0.009), 
calcium channel blockers (p=0.023) and angiotensin II receptor blockers (p=0.001). 
Conversely, the survivors were more frequently without any co-medication on hospital 
admission when compared to the non-survivors (37.8% vs 18.8%, p=0.016). 
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There were no significant between-group differences in terms of time from the onset of 
symptoms to hospital admission (overall median 7 days, IQR 4-9), and no significant 
differences in symptoms and signs upon admission. The most frequent presenting signs were 
fever, cough and dyspnea in both groups.  
A higher proportion of survivors had chest X-rays without any pathological findings (16.2% 
vs 4.2%; p=0.033), but there was no difference in the pathological X-ray patterns between the 
two groups. A higher proportion of non-survivors presented with severe or critical disease 
(p<0.001).  
Table 2 shows the baseline laboratory findings. The non-survivors had significantly lower 
median lymphocyte (p=0.008), hemoglobin (p=0.009) and albumin levels (p<0.001), and 
significantly higher median CRP (p<0.001), D-dimer (p<0.001) and creatinine levels 
(p<0.001). 
During the hospitalization 172 (73.8%) patients received a combination of LPV/r plus HCQ, 
39 (16.7%) with remdesivir of whom 33 (14.2%) after LPV/r plus HCQ and 42 (18%) with 
tocilizumbab of whom 35 (83.3%) after LPV/r plus HCQ. Ten patients received all the 3 
combinations. One hundred and forty-four (61.8%) patients were treated with at least one 
antibiotic during the hospital stay. 
The median follow-up of the cohort as a whole was 40 days (IQR 33-47): eleven days (IQR 6-
18) for the non-survivors and 44 days (IQR 38-49) for the survivors. The median hospital stay 
was 12 days (IQR 8-21). Kaplan Meier curve analysis showed that the time-dependent 
probability of death ten, 20 and 30 days after hospital admission was respectively 10.3% (95% 
confidence interval [CI] 6.4-14.2%), 16.3% (95% CI 11.6-21.1) and 19.7% (95% CI 14.6-
24.9%) (Fig. 1).  
Table 3 shows the uni- and multivariable Cox analysis of the factors associated with the risk 
of death. Age (adjusted hazard ratio [aHR] 2.08, 95% CI 1.48-2.92 per ten years more) and 
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obesity (aHR 3.04, 95% CI 1.42-6.49) were independently associated with an increased risk of 
death, which was also associated with critical disease (aHR 8.26, 95% CI 1.41-48.29), CRP 
levels (aHR 1.17, 95% CI 1.02-1.35 per 50 mg/L more) and CK levels above 185 U/L (aHR 
2.58, 95% CI 1.37-4.87) upon admission. Conversely, the multivariable model did not confirm 
the univariable findings of an increased risk of death in patients receiving at least one anti-
hypertensive agent, those with anemia, or those with D-dimer levels of >1000 μg/L upon 
admission. 
 
4. DISCUSSION 
We studied the characteristics and outcome of 233 adult COVID-19 patients hospitalised in 
Milan during the early dramatic days of the Italian epidemic.  Forty-eight patients (20.6%) died 
during the study period, with the probability of dying at 30 days from hospital admission being 
of 19.7%. The overall case fatality rate observed in our cohort was similar to that found in a 
recent study of 201 COVID-19 patients hospitalised in Wuhan [13], but higher when compared 
to the 14% estimated by Wu et al. in the early period of the epidemic in China [14]. 
In line with the findings of some Chinese studies [13,15], our patients were prevalently male, 
which suggests a gender-based need for different hospital care during SARS-CoV-2 infection. 
It has been suggested that males may be more prone to developing severe and fatal COVID-19 
[16, 17], and recent data regarding the epidemic in Europe shows a male-to-female death ratio 
of 2.1 that increases to 3.9 in patients aged 50–65 years  [18]. However, our multivariable 
analysis did not reveal a significant gender-based difference in the survival rate. The 
male/female ratio among the patients admitted to our hospital during study period was 2.24, 
and so the reasons for the findings of the preliminary European report may be that females are 
less likely to be hospitalised with COVID-19.  
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The median age of our patients was 61 years which was similar to that reported in a recent large 
case series from the New York city area (63 years, IQR 52-75) [19], as against the 47-56 years 
reported in studies of Chinese hospitals [20, 21]; like the fact that the proportion of our patients 
aged >75 years was 18.9%, this difference probably mirrors the demographic differences 
between Italy and China [22]. Preliminary data from Chinese studies indicated that COVID-19 
was more lethal in the elderly than younger people [13, 15], and we also found that an older 
age was an independent risk factor for death, as in the case of SARS and Middle East 
respiratory syndrome-related coronavirus [23, 24]. It has been speculated that older patients 
may be more likely to die of COVID-19 because age-related alterations in immunological 
functions and type 2 cytokine production lead to deficiencies in controlling SARS-CoV-2 
replication and pro-inflammatory responses [15].  
Our analysis showed that obese patients had a 3-fold higher risk of dying as compared to those 
with a body mass index below 30. This finding is in line with recently published studies 
suggesting that obesity represents one of the most important factors related to COVID-19 
severity as evidenced by higher need of hospitalization and of invasive mechanical ventilation 
[25, 26]. Several mechanisms have been proposed to explain the increased severity of COVID-
19 in obese patients, including the combination of reduced cardiorespiratory reserve and 
impairment of adaptive immune response to infections [27] It should be notice that the 
proportion of obese patients in our cohort was much lower than that recently described in a 
large case series by Richardson et al (16.3% vs 41.7%) and it cannot be excluded that in 
countries with high prevalence rate of obesity the effect of this condition on the burden of 
COVID-19 related mortality may be greater [19].  
In line with the findings of previous Chinese studies [13, 15], fever, cough and dyspnoea were 
the most frequent signs/symptoms at the time of hospital admission; however, there was no 
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significant difference between survivors and non-survivors in terms of symptoms upon 
admission. 
The most frequent chest X-ray alterations were monolateral consolidations and interstitial 
alterations, followed by bilateral lung consolidations; however, no lung alterations were 
detected at x-ray in 13.7% of cases.  
Most of our patients had mild or moderate disease [12] but, as expected, greater disease severity 
at the time of admission was strongly associated with an increased risk of death; in particular, 
the patients presenting with critical disease requiring assistance in ICU were at 8 times higher 
risk than those who did not.  
In line with the study by Luo et al we found that serum CRP level upon admission was 
independently associated with adverse outcome of COVID-19 [28]. It has been shown that in 
pulmonary diseases marked by inflammatory features there is a typical raise in serum CRP 
level in response to inflammatory cytokines such as IL-6, IL-1 or TNF-α. [29]. Thus, higher 
CRP level in non-survivors of our study may indicate excessive and dangerous inflammatory 
response. We also found a significant correlation between higher CK levels upon admission 
and the risk of death. Elevated level of CK in COVID-19 patients might be a sign of respiratory 
muscle injury resulting from the increased demands placed on the respiratory system. There 
also previous evidence suggesting that serum levels of CK may rise in patients with pneumonia 
and pulmonary embolic disease [30]. Furthermore, it cannot be excluded that the increase in 
CK values in COVID-19 may be related to a damage to CK-rich tissues, such as skeletal and 
cardiac muscle and brain, directly induced by the virus or maladaptive immune responses.  
Autopsy studies are required to define the damage of organs that can cause CK increase during 
COVID-9.  
Our study has a number of limitations. Firstly, as in China, the dramatically evolving scenario 
of the epidemic in Italy required continuous structural, organisational and staff changes that 
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exposed the study to maturation bias. In particular, the number of laboratory examinations 
performed upon admission was limited (i.e. Interleukine-6 determination became available 
only after 15 days from the start of the study). Secondly, only 14.8% of our patients underwent 
a chest computed tomography upon admission because of barriers in our infrastructure created 
in order to ensure a dedicated COVID-19 service. Thirdly, it was difficult to ascertain the 
different effects on outcomes of the miscellaneous and often concomitant drug treatments given 
to our patients because of the absence of a standard of care for COVID-19 (excluding oxygen 
supplementation). Nevertheless, as all of the patients admitted to our Infectious Diseases 
Department were enrolled in this study and the study population was probably representative 
of the COVID-19 patients hospitalised in Italy in the early stage of the epidemic.  
In conclusion, case-fatality rate of patients hospitalized with COVID-19 in the early days of 
the Italian epidemic was about 20%.  Older age, obesity, disease severity upon admission were 
factors related with increased risk of death. Further studies are needed to evaluate pathogenic 
mechanisms of SARS-CoV-2 and the effect of the several proposed therapeutic approaches in 
reducing its lethality. Moreover, long term post discharge follow-up is warranted to provide a 
more accurate estimate of the morbidity and mortality attributable to this infection. 
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Figure 1. Kaplan-Meier curve of the probability of survival over time in patients with SARS-
CoV-2 infection hospitalised in Milan, Italy. The continuous line represents the estimated 
survival curve, and the dashed lines the upper and lower limits of the 95% confidence interval. 
Table 1. Characteristics upon hospital admission of the COVID-19 patients who or died during the study period 
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Characteristic Total 
(n=233) 
Survivors 
(n=185) 
Non-survivors 
(n=48) 
P 
Gender, n (%) 
Male  
Female 
 
161 (69.1) 
72 (30.9) 
 
122 (65.9) 
63 (34.1) 
 
39 (81.2) 
9 (18.8) 
 
0.053 
Age in years, n (%) 
18-25 
26-35 
36-45 
46-55 
56-65 
66-75 
76-85 
86-95 
 
2 (0.9) 
16 (6.9) 
23 (9.9) 
37 (15.9) 
56 (24.0) 
55 (23.6) 
34 (14.6) 
10 (4.3) 
 
2 (1.1) 
16 (8.6) 
22 (11.9) 
35 (18.9) 
45 (24.3) 
36 (19.5) 
24 (13.0) 
5 (2.7) 
 
0 (0.0) 
0 (0.0) 
1 (2.1) 
2 (4.2) 
11 (22.9) 
19 (39.6) 
10 (20.8) 
5 (10.4) 
 
<0.001 
Transferred from other hospitals, n (%) 98 (42.1) 68 (36.8) 30 (62.5) 0.002 
History of smoking, n (%) 
No 
Yes 
 
163 (70.0) 
70 (30.0) 
 
132 (71.4) 
53 (28.6) 
 
31 (64.6) 
17 (35.4) 
 
0.362 
Obesity¥, n (%) 38 (16.3) 25 (13.5) 13 (27.1) 0.029 
Median age unadjusted Charlson Comorbidity Index (IQR) 0 (0-1) 0 (0-1) 1 (0-2) 0.002 
Medications received for chronic conditions, n (%)  
None 
Anti-platelet agents  
Anti-coagulant agents 
Acid-lowering agents  
Lipid-lowering agents 
At least one anti-hypertensive agent 
Calcium channel blockers 
Beta-blockers 
ARBs 
ACE inhibitors 
Diuretics 
Anti-arrhythmic agents  
Oral hypoglycemic agents 
Insulin 
Nervous system agents* 
Steroids/immunomodulators 
Inhaled steroids 
 
79 (33.9) 
33 (14.2) 
17 (7.3) 
41 (17.6) 
39 (16.7) 
85 (36.5) 
36 (15.5) 
33 (14.2) 
31 (13.3) 
31 (13.3) 
25 (10.7) 
10 (4.3)  
22 (9.4) 
7 (3.0) 
28 (12.0) 
9 (3.9) 
7 (3.0) 
 
70 (37.8) 
20 (10.8) 
12 (6.5) 
28 (15.1) 
28 (15.1) 
57 (30.8) 
23 (12.4) 
23 (12.4) 
17 (9.2) 
22 (11.9) 
16 (8.6) 
9 (4.9) 
17 (9.2) 
4 (2.2) 
20 (10.8) 
6 (3.2) 
4 (2.2) 
 
9 (18.8) 
13 (27.1) 
5 (10.4) 
13 (27.1) 
11 (22.9) 
28 (58.3) 
13 (27.1) 
10 (20.8) 
14 (29.2) 
9 (18.8) 
9 (18.8) 
1 (2.1) 
5 (10.4) 
3 (6.2) 
8 (16.7) 
3 (6.2) 
3 (6.2) 
 
0.016 
0.009 
0.355 
0.059 
0.199 
0.001 
0.023 
0.163 
0.001 
0.234 
0.064 
0.692 
0.784 
0.156 
0.318 
0.396 
0.156 
Median time from onset of illness (IQR), days 7 (4-9) 6 (4-9) 7 (4-9) 0.970 
Symptoms, n (%)     
Cough 
Dyspnea 
Sore throat 
Arthralgia/myalgia 
Headache 
Asthenia 
Vomiting and/or diarrhea 
121 (51.9) 
82 (35.2) 
11 (4.7) 
12 (5.2) 
12 (5.2) 
28 (12.0) 
24 (10.3) 
99 (53.5) 
67 (36.2) 
11 (5.9) 
11 (5.9) 
12 (6.5) 
21 (11.4) 
22 (11.9) 
22 (45.8) 
15 (31.2) 
0 (0.0) 
1 (2.1) 
0 (0.0) 
7 (14.6) 
2 (4.2) 
0.418 
0.612 
0.126 
0.468 
0.134 
0.618 
0.180 
Signs, n (%) or median (IQR)     
Fever >37.3 °C 
Body temperature (°C) 
156 (67.0) 
38 (37.3-38.6) 
125 (67.6) 
38.0 (37.2-38.6) 
31 (64.6) 
38.0 (37.4-38.4) 
0.732 
0.903 
Systolic blood pressure, mm Hg 125 (118-140) 125 (119-140) 130 (117-150) 0.421 
Diastolic blood pressure, mm Hg 75 (70-80) 75 (70-80) 75 (62.5-87.5) 0.881 
Pulse, beats per minute 86 (76-100) 86 (77-100) 83 (75-100) 0.806 
Respiratory rate, breaths per minute 21 (18-28) 20 (18-26) 24 (20-30) 0.009 
Percutaneous oxygen saturation, % 95 (93-97) 95 (93-97) 94.5 (90-97) 0.169 
X-ray signs of lung changes, n (%) 
No alterations 
Interstitial changes 
Monolateral consolidation(s) 
Bilateral consolidation(s) 
Pleural effusion 
 
32 (13.7) 
119 (51.1) 
139 (59.7) 
85 (36.5) 
17 (7.3) 
 
30 (16.2) 
100 (54.1) 
115 (62.2) 
71 (38.4) 
11 (5.9) 
 
2 (4.2) 
19 (39.6) 
24 (50.0) 
14 (29.2) 
6 (12.5) 
 
0.033 
0.078 
0.139 
0.313 
0.127 
Oxygen therapy, n (%) 
No 
Simple face mask  
Venturi-type oxygen mask  
Face mask with oxygen reservoir bag  
Continuous positive airway pressure (cPAP) 
Mechanical ventilation 
 
96 (41.2) 
49 (21.0) 
36 (15.5) 
15 (6.4) 
29 (12.4) 
8 (3.4) 
 
89 (48.1) 
35 (18.9) 
31 (16.8) 
10 (5.4) 
19 (10.3) 
1 (0.5) 
 
7 (14.6) 
14 (29.2) 
5 (10.4) 
5 (10.4) 
10 (20.8) 
7 (14.6) 
 
<0.0001 
Disease severity†, n (%)     
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Mild 
Moderate 
Severe 
Critical 
32 (13.7) 
113 (48.5) 
80 (34.3) 
8 (3.4) 
30 (16.2) 
94 (50.8) 
60 (32.4) 
1 (0.5) 
2 (4.2) 
19 (39.6) 
20 (41.7) 
7 (14.6) 
<0.001 
¥defined as a body mass index ≥30 [10] 
* Nervous system agents: anti-epileptics, benzodiazepine, anti-psychotics, anti-depressants.  
†As classified by Wu et al. [12].  
IQR = interquartile range; cPAP = continuous positive airway pressure; ARBs = Angiotensin II receptor blockers. 
 
Table 2. Laboratory findings upon admission 
     
 Median (IQR) or Number (%) 
Parameter Total 
(n=233) 
Survivors 
(n=185) 
Non-survivors 
(n=48) 
P 
White blood cell count x 109/L 
>10 x 109/L 
5.7 (4.4-7.5) 
  24 (10.3) 
5.5 (4.4-7.1) 
  13 (7.0) 
6.7 (4.8-9.0) 
  11 (22.9) 
0.006 
0.008 
Lymphocyte count x 109/L 
<8.0 x 109/L 
1.0 (0.7-1.3) 
  72 (30.9) 
1.0 (0.8-1.4) 
  52 (28.1) 
0.9 (0.6-1.1) 
  20 (41.7) 
0.008 
0.081 
Neutrophil count x 109/L 4.1 (2.8-6.0) 3.9 (2.8-5.3) 5.7 (3.8-8.3) <0.001 
Hemoglobin, g/dL 13.8 (12.6-14.8) 13.9 (13.0-14.8) 13.2 (11.7-14.3) 0.009 
Anemia*   111 (47.6)   79 (42.7)   32 (66.7) 0.003 
Platelets x 109/L 176 (137-221) 174 (137-221) 181 (141-226) 0.534 
Prothrombin, INR 1.2 (1.1-1.3) 1.2 (1.1-1.3) 1.2 (1.1-1.4) 0.188 
Fibrinogen, g/L  7 (6.3-7)   7 (6-7)   7 (7-7) 0.148 
D-dimer, g/L 
<500 
500-1000 
> 1000  
916 (535-1957) 
   51 (21.9) 
   77 (33.0) 
   105 (45.1) 
808 (494-1480) 
   49 (26.5) 
   63 (34.1) 
   73 (39.5) 
1740 (942-4851) 
   2 (4.2) 
   14 (29.2) 
   32 (66.7) 
<0.001 
 
0.001 
PaO2 , mmHg 69.5 (61-80.7) 70.5 (62.7-81.2) 64.5 (57.2-76.5) 0.022 
C-reactive protein, mg/L 
< 50 
50-100 
>100  
47.6 (20.0-118.7) 
  124 (53.2) 
  33 (14.2) 
  76 (32.6) 
40.9 (17.9-102.0) 
  108 (58.4) 
  28 (15.1) 
  49 (26.5) 
130.0 (40.0-203.5) 
  16 (33.3) 
  5 (10.4) 
  27 (56.2) 
<0.001 
 
0.001 
Creatinine, mg/dL 0.96 (0.79-1.2) 0.93 (0.76-1.1) 1.1 (0.96-1.68) <0.001 
Lactate dehydrogenase, U/L (n= 229) 338 (259-447) 305 (246-404) 438 (349-686) <0.001 
Creatine kinase, U/L 
> 185 
109 (62.0-237.0) 
  69 (29.6) 
93 (59.0-182.2) 
  43 (23.2) 
251 (106.7-392.0) 
  26 (54.2) 
<0.001 
<0.001 
Alanine aminotransferase (U/L) 32 (20-53) 30 (20-49) 40 (28-59) 0.018 
Bilirubin, mg/dL 1.2 (1.0-1.2) 1.2 (1.1-1.2) 1.1 (1.0-1.2) 0.509 
Albumin, g/L (n=222) 29 (25-33) 30 (26-34) 25 (23-30) <0.001 
*Anemia defined as a hemoglobin value of <12.5 g/dL for females and <14 g/dL for males.  
IQR = interquartile range; INR: International Normalised Ratio. 
 
Table 3. Cox regression analysis of the demographic and clinical factors associated with 
SARS-CoV-2 infection mortality 
 
Characteristic HR 95% CI P  aHR 95% CI P 
Gender 
  Female 
Male 
 
1 
2.02 
 
 
0.98-4.16 
 
 
0.058 
  
1 
1.42 
 
 
0.62-3.28 
 
 
0.409 
Age 
Per 10 years more 
 
1.81 
 
1.44-2.28 
 
<0.0001 
  
2.08 
 
1.48-2.92 
 
<0.0001 
Age unadjusted Charlson comorbidity index 
  Per one point more 
 
1.32 
 
1.12-1.57 
 
0.001 
  
1.07 
 
0.83-1.37 
 
0.605 
Obesity¥ 
   No 
   Yes 
 
1 
2.01 
 
 
1.07-3.81 
 
 
0.031 
  
1 
3.04 
 
 
1.42-6.49 
 
 
0.004 
Being treated with at least one anti-hypertensive 
agent  
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No 
Yes 
1 
2.78 
 
1.56-4.94 
 
<0.001 
1 
1.41 
 
0.73-2.74 
 
0.309 
Disease severity† 
Mild 
Moderate 
Severe 
Critical 
 
1 
2.82 
4.43 
35.35 
 
 
0.66-12.10 
1.04-18.97 
7.29-171.43 
 
 
0.163 
0.045 
<0.0001 
  
1 
1.30 
1.50 
8.26 
 
 
0.29-5.77 
0.32-7.04 
1.41-48.29 
 
 
0.727 
0.605 
0.019 
Presence of anemia° 
No 
Yes 
 
1 
2.43 
 
 
1.33-4.43 
 
 
0.004 
  
1 
1.31 
 
 
0.67-2.59 
 
 
0.429 
Lymphocyte count  
   Per 100 cells/μL more 
 
0.91 
 
0.00-0.97 
 
0.008 
  
0.98 
 
0.91-1.06 
 
0.664 
D-dimer  
  ≤1000 μg/L 
  >1000 μg/L 
 
1 
2.70 
 
 
1.45-5.02 
 
 
0.002 
  
1 
1.13 
 
 
0.57-2.23 
 
 
0.725 
C-reactive protein  
  Per 50 mg/L more  
 
1.26 
 
1.15-1.38 
 
<0.0001 
  
1.17 
 
1.02-1.35 
 
0.028 
Creatinine,  
  Per 0.5 mg/dL more 
 
1.08 
 
1.01-1.15 
 
0.030 
  
1.0 
 
0.92-1.1 
 
0.528 
Creatine kinase  
  ≤185 U/L 
  >185 U/L 
 
1 
3.26 
 
 
1.84-5.75 
 
 
<0.001 
  
1 
2.58 
 
 
1.37-4.87 
 
 
0.003 
¥ Obesity defined as body mass index ≥30 points [10]. 
†Disease severity classification  proposed by Wu et al. [12]: mild (mild clinical symptoms, no imaging signs of pneumonia); 
moderate (fever, cough, dyspnea or other symptoms, imaging signs of pneumonia); severe (any of: respiratory distress with 
respiratory rate (RR) of ≥30 breaths per minute; resting oxygen saturation  in air ≤93%; or PaO2 / FiO2 ≤300 mmHg); and 
critical (any of: respiratory failure requiring mechanical ventilation; shock; or  any other organ failure needing intensive 
care).  
*Anemia defined as hemoglobin <12.5 g/dL for females, and <14 g/dL for males. 
HR = hazard ratio; aHR = adjusted hazard ratio; CI = confidence interval. 
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